Investment Highlights for EmpowerPharm Inc.

EmpowerPharm Inc.
5575 North Service Road, Suite 603
Burlington, ON, L7L 6M1
Canada
Phone: (416) 291-2580
https://empowerpharm.ca/ 

• Innovative CBD Treatment for Social Anxiety Disorder (SAD). EmpowerPharm is at the forefront of developing a prescription-grade CBD therapy for SAD. Utilizing its proprietary SNEDDS technology, the Company enhances CBD’s bioavailability and effectiveness, offering a clinically validated, safer alternative in a market dominated by SSRIs and benzodiazepines, fulfilling the need for non-addictive treatments. 
  
  
• First Prescription CBD Pill for Social Anxiety. EmpowerPharm’s flagship product, developed with patent-pending SNEDDS technology, is a THC-free, non-intoxicating CBD pill specifically for SAD. Positioned to be the first CBD prescription approved for this use, the formulation provides a safer treatment option with potential support from insurance and government programs.
  
  
• Promising Phase 2 Results. Strong Phase 2 clinical outcomes demonstrate the effectiveness of EmpowerPharm’s CBD product for SAD, positioning the Company for a successful Phase 3 trial and, ultimately, commercialization.
  
  
• Federal Approval and Insurance Accessibility. With federal approval, the product can be established as a prescription drug, ideally covered by third-party insurance, which would significantly increase accessibility, sales, and market stability within this large market.
  
  
• Advanced, Patentable Drug Formulations. EmpowerPharm’s unique drug formulations based on SNEDDS technology increases CBD bioavailability and efficacy, providing therapeutic advantages and creating competitive barriers. These proprietary formulations also strengthen the Company’s intellectual property (IP) portfolio and offers potential applications for other low-bioavailability drugs.
  
  
• Meeting Unmet Needs in a Growing Market. SAD affects millions globally, with the treatment market projected to reach $16 billion by 2030. EmpowerPharm’s pharmaceutical-grade CBD capsule addresses a significant gap, providing a non-addictive alternative to current anxiety treatments, positioning the Company for competitive advantage in a rapidly growing field.
  
  
• Strong Intellectual Property Portfolio. The Company’s expanding IP portfolio secures market exclusivity, enhancing revenue potential from product sales.
  
  
• Scalable Manufacturing and Regulatory Positioning. EmpowerPharm’s GMP-certified facility in Ontario, the first in Canada licensed for cannabinoid-based products, supports R&D, clinical development, and commercial production. This scalable infrastructure positions EmpowerPharm for regulatory approvals in the U.S., Canada, and other key markets, establishing a solid presence in the pharmaceutical-grade CBD sector.
  
  
• High Pharmaceutical Profitability Potential. The Company’s patent-pending formulations and the high entry barriers in the pharmaceutical industry allow it to leverage strong profitability dynamics to meet growing demand for pharmaceutical-grade CBD solutions.
  
  
• Experienced R&D Team. EmpowerPharm’s R&D team brings decades of pharmaceutical expertise, with a proven track record in developing and commercializing solid oral dosage forms.
  
  
• Epidiolex Success as a Model. GW Pharma’s Epidiolex®—the first FDA-approved CBD drug for rare epilepsy—demonstrated the commercial viability of CBD, generating $845.5 million in 2023. EmpowerPharm differentiates itself by offering a convenient capsule form for SAD, compared to CBD oils.
  
  
• Funding and Strategic Direction. EmpowerPharm seeks $100 million in equity for Phase 3 trials, R&D, and scaling efforts, with funds to be disbursed over 2 to 3 years based on milestones. To date, CD$95 million has been raised, primarily from lead investor Aubrey Dan (66% ownership). The exit strategy includes potential M&A or IPO, positioning its pioneering CBD treatment for SAD as a high-value acquisition target.
  
  
• * Updated on November 18, 2024.